HIP
VRTX icon

Harrell Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Harrell Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
4,415
+66
+2% +$29.3K 0.48% 50
2026
Q1 		$1.94M Sell
4,349
-28
-0.6% -$13.1K 0.46% 54
2025
Q4 		$1.98M Buy
4,377
+12
+0.3% +$5.17K 0.47% 54
2025
Q3 		$1.71M Buy
4,365
+13
+0.3% +$5.43K 0.4% 57
2025
Q2 		$1.94M Buy
+4,352
New +$2.01M 0.49% 50

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Harrell Investment Partners's VRTX Position: Q2 2026 in Review

Harrell Investment Partners increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $29.3K and bringing the position to 4,415 shares worth $2.19M. The position accounts for 0.48% of the portfolio, ranked #50.

Harrell Investment Partners first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Harrell Investment Partners held 4,415 shares of Vertex Pharmaceuticals worth $2.19M as of Q2 2026.
  • Harrell Investment Partners bought 66 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
  • Vertex Pharmaceuticals made up 0.48% of Harrell Investment Partners's portfolio in Q2 2026, its #50 holding.
  • Harrell Investment Partners first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Harrell Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.